知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

4792 条记录 (耗时 0.042 秒)

    CELL-TO-CELL DELIVERY OF RNA CIRCUITS
    105.
    发明申请
    CELL-TO-CELL DELIVERY OF RNA CIRCUITS 有权

    公开(公告)号：US20230076395A1

    公开(公告)日：2023-03-09

    申请号：US17820232

    申请日：2022-08-16

    申请人： California Institute of Technology

    发明人： Richard F. Horns ,  Michael B. Elowitz ,  Joe A. Martinez

    IPC分类号： C12N15/88 ,  C12N15/62 ,  C12N15/86 ,  C07K14/005

    摘要： Disclosed herein include methods, compositions, and kits suitable for use in the delivery of polyribonucleotides and circuits. There are provided, in some embodiments, RNA exporter proteins comprising an RNA-binding domain, a membrane-binding domain, and an interaction domain capable of nucleating self-assembly. Disclosed herein include polynucleotides encoding cargo RNA molecule(s). In some embodiments, a plurality of RNA exporter proteins are capable of self-assembling into lipid-enveloped nanoparticles (LNs) secreted from a sender cell in which the RNA exporter proteins are expressed, thereby generating a population of LNs comprising a fusogen and exported cargo RNA molecule(s).

    HOMODIMER-TYPE BISPECIFIC ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF
    106.
    发明申请
    HOMODIMER-TYPE BISPECIFIC ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF 有权

    公开(公告)号：US20230073411A1

    公开(公告)日：2023-03-09

    申请号：US17290728

    申请日：2019-10-28

    申请人： AMPSOURCE BIOPHARMA SHANGHAI INC.

    发明人： Qiang Li ,  Shixiang Jia ,  Xinlu Ma ,  Yuan Yan ,  Yuhua Zhang ,  Yuanli Li

    IPC分类号： C07K16/28 ,  A61P35/00 ,  C12N15/85 ,  C12N15/62

    摘要： A tetravalent, homodimer-type bispecific antibody molecule that simultaneously targets immune effector cell antigen CD3 and human epidermal growth factor receptor 2 (Her2); the bispecific antibody molecule comprises, from in sequence from N-terminus to C-terminus, a first single-chain Fv capable of specifically binding to Her2, a second single-chain Fv capable of specifically binding to CD3, and an Fc fragment; the first and second single-chain Fv are connected by means of a connection peptide, and the second single-chain Fv is connected to the Fc directly fragment or is connected by means of a connection peptide; the Fc fragment does not have effector functions such as CDC, ADCC and ADCP. The bispecific antibody may significantly inhibit or kill tumor cells, and has controlled toxic side effects that may be caused by excessive activation of effector cells. The maximum safe starting dose in preclinical toxicology evaluation tests is significantly higher than other doses having the same target, and no systemic immunotoxicity occurs, suggesting that the drug administration safety window for the bispecific antibody is wide; in addition, said bispecific antibody is a homodimer that does not experience the problem of heavy chain and light chain mismatching; the steps of purification are simple and efficient, expression is high, and the physicochemical and in vivo stability of the antibody are significantly improved.

    EXPORTED RNA REPORTERS FOR LIVE-CELL MEASUREMENT
    107.
    发明申请
    EXPORTED RNA REPORTERS FOR LIVE-CELL MEASUREMENT 有权

    公开(公告)号：US20230071834A1

    公开(公告)日：2023-03-09

    申请号：US17820235

    申请日：2022-08-16

    申请人： California Institute of Technology

    发明人： Richard F. Horns ,  Michael B. Elowitz

    IPC分类号： C12N15/10 ,  C12N15/11 ,  C12N15/62

    摘要： Disclosed herein include methods, compositions, and kits suitable for use in the measurement of the states of living cells across time. There are provided, in some embodiments, RNA exporter proteins comprising an RNA-binding domain, a membrane-binding domain, and an interaction domain capable of nucleating self-assembly. Disclosed herein include polynucleotides encoding reporter RNA molecule(s). In some embodiments, a plurality of RNA exporter proteins are capable of self-assembling into lipid-enveloped nanoparticles (LNs) secreted from a reporter cell in which the RNA exporter proteins are expressed, thereby generating a population of LNs comprising exported reporter RNA molecule(s).

    Method for producing a condensed adhesive phase of silk fusion proteins
    109.
    发明授权
    Method for producing a condensed adhesive phase of silk fusion proteins 有权

    公开(公告)号：US11597750B2

    公开(公告)日：2023-03-07

    申请号：US16622301

    申请日：2018-06-13

    申请人： Aalto University Foundation sr

    发明人： Markus Linder ,  Pezhman Mohammadi ,  Sesilja Aranko

    IPC分类号： C07K14/435 ,  C07K1/02 ,  C07K14/33 ,  D01D1/02 ,  D01F4/00 ,  C12N15/62 ,  A61L27/36

    摘要： The present invention is directed to a method for producing a condensed phase of a silk fusion protein, the method comprising the steps of preparing a solution of a silk fusion protein in an aqueous medium and concentrating the silk fusion protein in the aqueous medium, wherein the fusion protein is isolated from a recombinant production host and comprises a silk-like protein sequence and two separate non-silk terminal module sequences, such as cellulose binding modules, SpyCatcher domains, tenth type III module of Fibronectin, gamma-crystallin D, flanking the silk-like protein sequence; wherein the method is performed so that the silk fusion protein is not precipitated and subsequently dissolved to the aqueous medium. The present invention is also directed to using such fusion proteins as adhesives.

    IMPROVED VARIANTS OF TEV PROTEASE FOR BIOTECHNOLOGICAL APPLICATIONS
    110.
    发明申请
    IMPROVED VARIANTS OF TEV PROTEASE FOR BIOTECHNOLOGICAL APPLICATIONS 有权

    公开(公告)号：US20230067225A1

    公开(公告)日：2023-03-02

    申请号：US17642635

    申请日：2020-09-24

    申请人： Chan Zuckerberg Biohub, Inc. ,  The Board of Trustees of the Leland Stanford Junior University

    发明人： Alice Y. Ting ,  Mateo Isidro Sanchez Lopez

    IPC分类号： C12P21/02 ,  C12N9/50 ,  C12N15/62 ,  C12N15/10

    摘要： Tobacco etch virus protease (TEV) is one of the most widely used proteases in biotechnology because of its exquisite sequence-specificity. A limitation of TEV is its slow catalytic rate, which limits product generation and therefore signal output. Provided is a generalizable yeast-based platform for directed evolution of protease catalytic properties. Protease activity is determined via proteolytic release of a membrane-anchored transcription factor, and access to TEV's cleavage site is temporally regulated using a photosensory LOV domain. By gradually decreasing light exposure time, faster variants of TEV were selected over multiple rounds of selection. The mutant TEV proteases and the directed evolution platform are useful in a wide range of biotechnology applications, such as FLARE and SPARK tools.